Antonio Cuneo

Ferrara, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 188 publications

Vitamin K Antagonist Treatment Burden Assessed with the Patient Reported Outcome "Anti Clot Treatment Scale": KAFe Trial, a Single-Center Study Involving 202 Patients.

Vitamin K Antagonist Treatment Burden Assessed with the Patient Reported Outcome "Anti Clot Treatment Scale": KAFe Trial, a Single-Center Study Involving 202 Patients.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: July 30, 2026

Minimal residual disease in CLL: when does it really matter?

Minimal residual disease in CLL: when does it really matter?

Journal: Blood
Published: June 11, 2026

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Journal: Cancers
Published: January 08, 2026

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

Journal: BMC health services research
Published: October 28, 2025

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Journal: British journal of haematology
Published: September 07, 2025

Exploring the synergy between telomere length and genomic complexity in CLL.

Exploring the synergy between telomere length and genomic complexity in CLL.

Journal: British journal of haematology
Published: August 20, 2025

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Journal: Leukemia
Published: May 20, 2025

18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study.

18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study.

Journal: Cancers
Published: April 23, 2025

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.

Journal: Journal of hematology & oncology
Published: April 15, 2025

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations.

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B-cell-related epigenetic imprinting and genetic alterations.

Journal: HemaSphere
Published: February 24, 2025

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Journal: Leukemia
Published: January 09, 2025

Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.

Journal: Blood advances
Published: January 07, 2025
Showing 1-12 of 188

Last Updated: 09/26/2026